Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Licarbazepine in Bipolar I Disorder (Extension)
NCT00238485Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2005
- Primary completion
- Jul 2007
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of licarbazepine in bipolar I disorder, sponsored by Novartis. Primary endpoints: Adverse Events at 52 weeks, Serious Adverse Events at 52 weeks and 3 more. Started Jan 2005; status: completed.
02
Drugs
licarbazepine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00238485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238485.